Return to homepagePandemic Pact

UNI911 - TRIPLE-action inhalation treatment for COVID-19

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Innovationsfonden Denmark

  • Principal Investigator

    N/A

  • Research Location

    Denmark

  • Lead Research Institution

    UNION therapeutics A / S, together with i.a. Trial Nation and Bispebjerg hospital

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Old drug against tapeworm is now being tested as a treatment for COVID-19. UNI911 from Danish UNION therapeutics A / S is based on a both known and safe drug that is used for e.g. treatment of tapeworms. The active substance in the medicine is on the WHO's list of essential medicines, and in UNI911 it is combined with excipients in a completely new composition. UNI911 has potential in the treatment of COVID-19 as it contains both antibacterial and anti-inflammatory properties and shows great potential to eliminate the virus in the respiratory tract and reduce inflammation in the lung tissue caused by the infection. The purpose of the project is to perform the crucial clinical tests so that one can verify both the efficacy and the safety of using UNI911. The first phase is testing on healthy volunteers who are continuously tested and monitored for their lung function.